GlassScriptPhysician profile
Jordan D Skyer
NPI 1568462075
$3,885.33
in general payments reported to CMS, 2019-2025
29 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $210 · 2021: $444 · 2022: $654 · 2023: $575 · 2024: $599 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.24 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $290.24 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $281.38 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $267.64 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $242.28 | 2022 | |
| Kala Pharmaceuticals, INC. | $177.89 | 2021 | |
| Oyster Point Pharma, INC. | $169.50 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $157.47 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $150.00 | 2025 | Dextenza |
| Biotissue Holdings INC. | $134.90 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $131.53 | 2024 | |
| Genzyme Corporation | $131.40 | 2022 | |
| Rxsight INC | $130.96 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.18 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.59 | 2023 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $120.06 | 2025 | Oxervate |
| Coopervision INC. | $119.00 | 2019-2021 | |
| Amgen INC. | $117.68 | 2025 | Tepezza |
| Lkc Technologies, INC. | $116.09 | 2023 | |
| Asd Specialty Healthcare, LLC | $104.50 | 2019 | |
| Alcon Vision LLC | $71.86 | 2019-2025 | Simbrinza, Rocklatan |
| Maculogix, INC. | $68.20 | 2019 | |
| Allergan, INC. | $63.53 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $62.76 | 2020-2022 | |
| Visioneering Technologies, INC. | $50.13 | 2020 | |
| Eyevance Pharmaceuticals LLC | $44.15 | 2019-2021 | |
| Optos, INC. | $40.82 | 2020 | |
| Mallinckrodt Enterprises LLC | $19.99 | 2019 | |
| Aerie Pharmaceuticals, INC. | $18.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Skyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.